Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).
Lim, Eun-Jin, Ahn, Yo-Chan, Jang, Eun-Su et al. · Journal of translational medicine · 2020 · DOI
Quick Summary
This study looked at 45 research projects involving over 1 million people to estimate how many people have ME/CFS worldwide. The researchers found that about 0.68% of the general population (roughly 1 in 150 people) has ME/CFS, though the number varies depending on who was studied and how the diagnosis was made. Women are about 1.5 to 2 times more likely to have ME/CFS than men.
Why It Matters
This comprehensive prevalence estimate provides researchers and clinicians with the most current global overview of ME/CFS burden and highlights critical gaps in diagnostic standardization that affect how many people are identified with the disease. For patients, understanding the true prevalence supports advocacy efforts and helps validate that ME/CFS is a significant population-level health problem, not a rare condition.
Observed Findings
Meta-analysis prevalence estimates varied significantly: women 1.36% vs. men 0.86%, community-based samples 0.76% vs. primary care sites 0.63%, and adults ≥18 years 0.65% vs. children <18 years 0.55%.
Case definition choice influenced prevalence: CDC-1994 definition 0.89% vs. Holmes definition 0.17%.
Over 1 million participants across 45 studies were analyzed, with 540,901 from community surveys and 545,075 from primary care sites.
Inferred Conclusions
Current ME/CFS prevalence is approximately 0.68-0.89% globally, with women experiencing 1.5-2 fold higher rates than men across all population categories.
Large variations in reported prevalence are primarily driven by inconsistent case definitions and diagnostic methodologies rather than true epidemiological differences.
Objective, standardized diagnostic criteria are urgently needed to enable accurate prevalence assessment and consistent identification of ME/CFS cases across populations.
Remaining Questions
Why do different diagnostic methods (interviews vs. physician diagnosis) produce such dramatically different prevalence estimates (1.14% vs. 0.09%), and which approach better identifies true cases?
What explains the consistent 1.5-2 fold female predominance across all studies—biological, diagnostic, or reporting differences?
What This Study Does Not Prove
This study does not establish the causes of ME/CFS or explain why women have higher prevalence rates. It also does not prove that any particular diagnostic method is superior—rather, it demonstrates that different methods produce different prevalence estimates, highlighting a methodological problem rather than providing a gold standard. The wide variation in findings suggests prevalence estimates may not reflect true disease burden without standardized diagnostic criteria.
Tags
Symptom:Fatigue
Phenotype:Pediatric
Method Flag:PEM Not DefinedWeak Case DefinitionMixed Cohort
How would prevalence estimates change if a single, objective diagnostic biomarker or standardized assessment tool were universally adopted?
Do true disease prevalence rates vary by country and population characteristics, or are observed differences purely artifacts of methodological variation?